Skip to content
DataLookout
Menu

FIPSNCT07475455

Filler Post Market Survey (FIPS)

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Primary completion date changed from estimate of Oct 15, 2026 to Aug 15, 2026
    • Secondary endpoints: details revised at 4 of 6 entries
  2. Minor Enrollment increased: 30 → 33 participantsv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in nasolabial fold severity on a 5-grade photonumeric scale
Timeframe: Baseline (Visit 1) to 6 months post-treatment (Visit 3; 6 months ± 14 days)

Secondary (6)

Maximum volume administered per treatment
Maximum dose administered without safety concerns
Incidence of adverse events and adverse device effects
Visible aesthetic change in nasolabial fold severity
Aesthetic improvement based on modified GAIS
Show 1 moreShow less
Participant satisfaction with aesthetic outcome

Arms and interventions

Participants treated with saypha® filler for nasolabial fold correction

Participants who received routine clinical treatment of moderate to severe nasolabial folds using saypha® filler. Data will be collected prospectively after treatment and retrospectively from existing medical records. No study-specific interventions are performed; all assessments derive from standard clinical practice, including NLF severity scores, aesthetic improvement ratings, administered volumes, and safety outcomes.

Devices: Hyaluronic acid dermal filler (routine clinical use)

Sites

1 site in 1 country

  • YuvellVienna, Austria